(Q43282311)

18 November 2017

title

Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia (English)

1 reference

18 November 2017

0 references

1 reference

Evangelos N Liberopoulos

5

1 reference

18 November 2017

Matilda Florentin

1

1 reference

18 November 2017

Michael S Kostapanos

2

1 reference

18 November 2017

Eleni S Nakou

3

1 reference

18 November 2017

Moses Elisaf

4

1 reference

18 November 2017

publication date

1 September 2009

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

18 November 2017

published in

1 reference

18 November 2017

volume

14

1 reference

18 November 2017

issue

4

1 reference

18 November 2017

page(s)

274-282

1 reference

Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Trends in serum lipids and lipoproteins of adults, 1960-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Diagnosis and management of the metabolic syndrome in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

The effects of orlistat on metabolic parameters and other cardiovascular risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

The emerging role of the endocannabinoid system in endocrine regulation and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Statin-associated adverse effects beyond muscle and liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Ezetimibe-associated adverse effects: what the clinician needs to know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

The hospital anxiety and depression scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Effect of orlistat on cardiovascular disease risk in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Effects of orlistat on obesity-related diseases - a six-month randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Multiple actions of high-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Prevention and treatment of the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409343935

21 January 2018

Identifiers

DOI

10.1177/1074248409343935

1 reference

18 November 2017

1 reference